Financial risk of increasing the follow-up period of breast cancer treatment currently covered by the Social Protection System in Health in México

Rodríguez-Aguilar, Román; Marmolejo-Saucedo, José Antonio; Tavera-Martínez, Sonia

doi:10.1186/s12962-018-0094-y

Cited by 13 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cochran–Armitage tests were performed to examine for statistical significance in trends of each and all ULT uses over the study period. Observed incidence and prevalence and demographic changes can be used in a simulation model to predict future overall healthcare costs and the financial impacts in the target population [15]. Time series modeling techniques for forecasting the future value, describing the pattern of change in a variable, and assessing the impacts of event have been increasing used in drug utilization research [16,17].…”

Section: Methodsmentioning

confidence: 99%

“…The effects on healthcare spending of changes in insurance coverage of innovative prescription drugs have previously been described in different disease populations [15,16], yet the aggregate demand for prescriptions associated with coverage expansions and therapeutic substitutions in management of hyperuricemia and gout are not well understood. We conducted a cross-sectional study to evaluate how the adoption of febuxostat and the modifications in its insurance coverage have affected trend changes in the ULT use and expenditure in a large Taiwan medical organization.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice

et al. 2019

View full text Add to dashboard Cite

Objectives Changes in treatment choice of therapy and size of treated population that can lead to under- or overestimate of payer’s budget are less likely to be reassured after reimbursement adoption of a new drug. The aim of this study was to evaluate the effects of febuxostat introduction and the modifications in its insurance coverage on the utilization and expenditure of urate-lowering therapy (ULT). Methods Electronic medical records for adults patients prescribed any ULT during 2010–2015 was derived from the largest medical organization in Taiwan. Aggregated estimates of ULT use and costs were assessed per 3-month and per patient per month (PPPM). Factors associated with total ULT expenditure were assessed using a time series design with factored Autoregressive Integrated Moving Average (ARIMA) models. Results ULT prevalent users increased 34.1% from 2010 to 2015 and a 123% increase in total ULT expenditure. Numbers on allopurinol and sulfinpyrazone both declined 31%, and on benzbromarone and febuxostat gradually increased to 38.21% and 22.89% of all users in 2015. Insurance payments PPPM ($4.44 to $9.22) and total monthly ULT cost ($32,946 to $ 85,732) growth more than doubled in 6 years, trend changes generated mostly by individuals switching to febuxostat. Conclusions ULT use moved to favor benzbromarone and febuxostat; greater expensive uptake for febuxostat led to a rapid rise in ULT cost. Marginal values of increasing access to febuxostat for asymptomatic hyperuricemia should be focus on future studies to facilitate drug prices negotiation and ensure appropriate ULT use.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In 2017, Mantovani and Galvao believed that the acquisition of historical credit records of financing enterprises directly affected the feasibility of financing receivables [19]. In 2017, Chicaiza-Becerra and Garcia-Molina regarded various risks of supply chain finance as a whole, and built a model by value at risk (VaR) method to measure the comprehensive risks of credit risks, market risks and operational risks [20]. In 2017, in the context of economic globalization, Seaman et al proposed that the premise of effective implementation of supply chain financial risk management was to identify risks, and then to take positive measures to deal with risks, so as to truly reduce risks and realize profits [21].…”

Section: Literature Reviewmentioning

confidence: 99%

Construction of Supply Chain Financial Risk Management Mode Based on Internet of Things

Wang

2019

IEEE Access

View full text Add to dashboard Cite

The objective of this paper is to analyze the problems of information asymmetry, mode lag, and high operational risk between banks and enterprises in the practice of supply chain finance business. In this paper, first, the concept and function of supply chain finance were elaborated, and the theoretical basis of supply chain financial risk control was studied. The implement of principal agent, information asymmetry theory, and self-compensated trade finance theory on realizing the risk avoidance in the actual development process was analyzed. Then, the business processes of the three basic financing models of supply chain finance and the shortcomings in the operation of each model were proposed. On this basis, risk sources and influencing factors of supply chain finance were analyzed, and operational risks were emphasized. Finally, a new financing mode of inventory pledge was designed based on the special function of Internet of Things (IoT) technology and the business process of inventory financing mode. The results showed that there was a big gap in the value of risk loss caused by various types of loss events in the operation risk of supply chain finance inventory pledge financing mode; among them, the biggest losses were from external fraud. By comparing the expected loss (ES) value of inventory pledge financing mode based on the IoT with the operation risk of traditional mode, it could be found that the supply chain finance mode based on the IoT technology effectively reduced the operation risk. Therefore, the system designed in this paper has certain reference and practical significance for financial risk management.

show abstract

“…Evidence is scarce on costs incurred by patients with OPMD and on the predictors associated with such costs in India. Evidence suggests that financial protection mechanisms are beneficial in reducing morbidity as well as mortality among cancer patients [ 10 , 11 ]. We conducted this study to estimate the costs incurred by patients for the care of OPMD and to determine the predictors of such costs in the Bhavnagar district of Gujarat (western India).…”

Section: Introductionmentioning

confidence: 99%

Costs incurred by patients with oral potentially malignant disorders: is there a public health need for financial protection in India?

Patel

Rupani

2021

BMC Res Notes

View full text Add to dashboard Cite

Objectives Financial protection mechanisms are in place to overcome the costs of a few diseases in India. Our objective was to estimate the costs incurred due to Oral Potentially Malignant Disorders (OPMD) and to determine predictors of such costs. Results We found that the median (Interquartile range IQR) total costs of OPMD was Indian Rupees (INR) 500 (350–750), direct medical costs was INR 0 (0–50), direct non-medical costs was INR 150 (40–200) and indirect costs was INR 350 (250–500). The travel cost to attend the health facilities [INR 100 (40–150)] and the patient’s loss of wages [INR 200 (150–400)] mainly accounted for the direct non-medical and indirect costs respectively. The median expenditure on smokeless and smoking forms of tobacco was INR 6000 (5400–7200) and INR 2400 (1800–3600) respectively. On multiple linear regression analysis, rural residence, belonging to below poverty line family, being a sole earner in the family, number of months since diagnosis and first visit at a private provider were found to be the significant predictors of total costs of OPMD. Financial protection mechanisms are needed for covering the direct non-medical and indirect costs. Early management of OPMD might mitigate the costs of OPMD.

show abstract

Financial risk of increasing the follow-up period of breast cancer treatment currently covered by the Social Protection System in Health in México

Cited by 13 publications

References 4 publications

The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice

The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice

Construction of Supply Chain Financial Risk Management Mode Based on Internet of Things

Costs incurred by patients with oral potentially malignant disorders: is there a public health need for financial protection in India?

Contact Info

Product

Resources

About